Revolution Medicines Inc. (42Z)
Summary
42Z Chart
High Risk, High Reward: Inside The Revolution Medicines Bull Case
Revolution Medicines is evolving from a clinical-stage biotech to a near-term commercial oncology player, anchored by its RAS(ON) inhibitor platform. RVMD's robust $3.9 billion cash position and additional committed capital support aggressive pipeline expansion and commercial launch readiness, reducing near-term dilution risk. Daraxonrasib's potential FDA approval and commercial launch in pancreatic cancer could fundamentally transform RVMD's financial profile and validate its broader RAS-targeted strategy.
RVMD Posts Wider-Than-Anticipated Loss in Q2, Lifts '26 Expense View
Revolution Medicines posts a wider-than-expected loss in Q2 and raises its 2026 expense outlook again as investors weigh higher spending and pipeline progress.
Revolution Medicines Q2 Earnings Call Highlights
Revolution Medicines NASDAQ: RVMD said its second-quarter 2026 results reflected continued investment in late-stage cancer programs, commercial launch preparations and manufacturing capacity as it advances daraxonrasib and other RAS-targeted therapies across pancreatic and lung cancer.
Revolution Medicines Inc. (42Z) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Revolution Medicines Inc. ever had a stock split?
Revolution Medicines Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mark A. Goldsmith CEO | XMUN Exchange | US76155X1000 ISIN |
| US Country | 883 Employees | - Last Dividend | - Last Split | 13 Feb 2020 IPO Date |
Overview
Revolution Medicines, Inc. is a clinical-stage company that focuses on precision oncology, specifically targeting RAS-addicted cancers, which are notoriously challenging to treat. The company leverages its expertise in the field to develop innovative therapies designed to inhibit the RAS signaling pathway, a critical driver in many forms of cancer. With a research and development pipeline featuring a variety of RAS(ON) inhibitors and RAS companion inhibitors, Revolution Medicines employs both monotherapy and combination treatment strategies to potentially improve outcomes for patients with these aggressive cancers. Founded in 2014, the company is headquartered in Redwood City, California, positioning itself at the forefront of cancer research with a clear focus on addressing unmet medical needs in the oncology space.
Products and Services
- RMC-6236 (multi): This RAS(ON) inhibitor is currently in phase 1 clinical trial. It exemplifies the company's approach to developing targeted therapies that can be used both as standalone treatments and in combination with other inhibitors or therapeutic agents.
- RMC-6291 (G12C): Also in phase 1 clinical trials, RMC-6291 targets specific mutations within the RAS gene, showcasing Revolution Medicines' commitment to precision oncology by tailoring treatments to the genetic profile of a patient's cancer.
- RMC-9805 (G12D): This development candidate is another example of the company's RAS(ON) inhibitors, focusing on a distinct mutation and currently undergoing phase 1 clinical trials to evaluate its effectiveness and safety.
- Development Candidates (RMC-5127, RMC-0708, RMC-8839): These candidates, including RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), are in various stages of pre-clinical and early clinical development. They represent the next wave of potential treatments targeting a variety of RAS mutations.
- RAS Companion Inhibitors (RMC-4630, RMC-5552):
- RMC-4630 is currently in phase 2 clinical trials. It exemplifies the company's efforts to develop drugs that can be used in combination with their RAS(ON) inhibitors to provide comprehensive treatment solutions.
- RMC-5552 is in phase 1 clinical trial, further expanding the range of the company's portfolio with the goal of offering more effective combination therapy options for patients fighting RAS-addicted cancers.
